Investigation on the DNA Repaired Gene Polymorphisms and Response to Chemotherapy and Overall Survival of Osteosarcoma

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Mar 11

PMID 25755792

Citations 16

Authors

Wei-Ping Ji

Neng-Bin He

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to evaluate the influence of polymorphisms in NER and HRR pathways on the response to cisplatin-based treatment and clinical outcome in osteosarcoma patients. 214 osteosarcoma patients treated with cisplatin-based chemotherapy were collected between January 2008 and January 2011. Genotypes of ERCC1 rs11615, ERCC2 rs1799793 and rs13181, NBN rs709816, RAD51 rs1801320, and XRCC3 rs861539 were conducted by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) assay. By conditional logistic regression analysis, patients carrying CC genotype of ERCC1 rs11615 showed a significant more good responder than TT genotype, and the OR (95% CI) was 2.51 (1.02-6.85). In the Cox proportional hazards model, after adjusting for potential confounding factors, we found that individuals carrying CC genotype of ERCC1 rs11615 was associated with decreased risk of death from osteosarcoma, and the HR (95% CI) was 0.43 (0.15-0.93). In conclusion, our results suggest that ERCC1 rs11615 polymorphism in the DNA repair pathways play an important role in the response to chemotherapy and overall survival of osteosarcoma.

Citing Articles

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Salazar J, Arranz M, Martin-Broto J, Bautista F, Martinez-Garcia J, Martinez-Trufero J Pharmaceutics. 2025; 16(12.

PMID: 39771563 PMC: 11677811. DOI: 10.3390/pharmaceutics16121585.

Loss Enhances Disease Progression in a Murine Model of Osteosarcoma.

Fatema K, Wang Y, Pavek A, Larson Z, Nartker C, Plyler S Cancers (Basel). 2024; 16(15).

PMID: 39123453 PMC: 11311538. DOI: 10.3390/cancers16152725.

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.

Wu X, Lu W, Jiang C, Zhang D, Zhang W, Cui Y PLoS One. 2023; 18(5):e0284825.

PMID: 37141338 PMC: 10159199. DOI: 10.1371/journal.pone.0284825.

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.

Hattinger C, Casotti C, Patrizio M, Luppi S, Fantoni L, Scotlandi K Int J Mol Sci. 2022; 23(19).

PMID: 36233089 PMC: 9570120. DOI: 10.3390/ijms231911787.

Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer.

Ozoran E, Trabulus F, Erhan D, Batar B, Guven M Int J Breast Cancer. 2022; 2022:5817841.

PMID: 35320970 PMC: 8938079. DOI: 10.1155/2022/5817841.

References

Gao R, Reece K, Sissung T, Reed E, Price D, Figg W . The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res. 2011; 708(1-2):21-7. PMC: 3057957. DOI: 10.1016/j.mrfmmm.2011.01.002. View

Li J, Liu S, Wang W, Zhang K, Liu Z, Zhang C . ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol. 2014; 35(10):10129-36. DOI: 10.1007/s13277-014-2322-1. View

Park S, Kong S, Nam B, Choi I, Kim C, Lee J . CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011; 104(7):1126-34. PMC: 3068488. DOI: 10.1038/bjc.2011.24. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Shen X, Lu F, Wu Y, Zhao L, Lin Z . XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PLoS One. 2013; 8(8):e69553. PMC: 3734199. DOI: 10.1371/journal.pone.0069553. View

Costa R, Chigancas V, Galhardo R, Carvalho H, Menck C . The eukaryotic nucleotide excision repair pathway. Biochimie. 2004; 85(11):1083-99. DOI: 10.1016/j.biochi.2003.10.017. View

Yang L, Li X, Bao C . Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev. 2013; 13(11):5883-6. DOI: 10.7314/apjcp.2012.13.11.5883. View

Hao T, Feng W, Zhang J, Sun Y, Wang G . Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev. 2012; 13(8):3821-4. DOI: 10.7314/apjcp.2012.13.8.3821. View

Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D . ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenet Genomics. 2013; 23(11):597-604. DOI: 10.1097/FPC.0b013e3283653afc. View

10.

Metzger R, Warnecke-Eberz U, Alakus H, Kutting F, Brabender J, Vallbohmer D . Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2011; 16(1):26-34. DOI: 10.1007/s11605-011-1700-x. View

11.

Moore D, Luu H . Osteosarcoma. Cancer Treat Res. 2014; 162:65-92. DOI: 10.1007/978-3-319-07323-1_4. View

12.

Chou A, Gorlick R . Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6(7):1075-85. DOI: 10.1586/14737140.6.7.1075. View

13.

Marsh S, Mcleod H, Dolan E, Shukla S, Rabik C, Gong L . Platinum pathway. Pharmacogenet Genomics. 2009; 19(7):563-4. PMC: 4153753. DOI: 10.1097/FPC.0b013e32832e0ed7. View

14.

Wang Q, Milum K, Han C, Huang Y, Wani G, Thomale J . Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer. 2011; 10:24. PMC: 3064653. DOI: 10.1186/1476-4598-10-24. View

15.

Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolzan V . DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. J Thorac Oncol. 2012; 7(10):1609-17. DOI: 10.1097/JTO.0b013e3182653d31. View

16.

Quartuccio N, Treglia G, Salsano M, Mattoli M, Muoio B, Piccardo A . The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol. 2013; 47(2):97-102. PMC: 3691088. DOI: 10.2478/raon-2013-0017. View

17.

Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J . Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011; 15(3):159-66. DOI: 10.1007/BF03256406. View

18.

Caronia D, Patino-Garcia A, Milne R, Zalacain-Diez M, Pita G, Alonso M . Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009; 9(5):347-53. DOI: 10.1038/tpj.2009.19. View

19.

Xu J, Hu L, Huang M, Zhao W, Yin Y, Hu Z . Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac J Cancer Prev. 2012; 13(3):851-6. DOI: 10.7314/apjcp.2012.13.3.851. View